

# EUROPEAN JOURNAL OF NANOMEDICINE

## **EDITORS-IN-CHIEF**

*Patrick Hunziker, University Hospital Basel, Switzerland*

*Jan Mollenhauer, University of Southern Denmark, Odense, Denmark*

## **SCIENTIFIC MANAGING EDITOR**

*Georgette B. Salieb-Beugelaar, University Hospital Basel, Switzerland*

## **MANAGING EDITOR CLINAM**

*Beat Löffler, European Foundation for Clinical Nanomedicine, Basel, Switzerland*

## **EDITORS**

*Christoph Alexiou, University Hospital Erlangen, Germany*

*Yechezkel Barenholz, The Hebrew University of Jerusalem, Israel*

*Kenneth Dawson, University College Dublin, Ireland*

*Rutledge Ellis-Behnke, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA*

*Bengt Fadeel, Karolinska Institute, Stockholm, Sweden*

*Silke Krol, Neurological Institute Foundation Carlo Besta, Milan, Italy*

*Dong Soo Lee, Seoul National University, Seoul, South Korea*

*Claus-Michael Lehr, Saarland University, Saarbrücken, Germany*

*Eder Lilia Romero, Quilmes National University, Bernal, Buenos Aires, Argentina*

*Simó Schwartz, Vall d'Hebron University Hospital, Barcelona, Spain*

*Janos Szebeni, Semmelweis University, Budapest, Hungary*

## **EDITORIAL BOARD**

*Ghaleb Husseini, American University of Sharjah, Sharjah, United Arab Emirates*

*Harald Mangge, Medical University of Graz, Graz, Austria*

*Bert Müller, University of Basel, Switzerland*

*Dan Peer, Tel Aviv University, Tel-Aviv, Israel*

*Giacinto Scoles, Princeton University, Princeton, New Jersey, USA*

*Patrick W. Serruys, Erasmus University Medical Center, Rotterdam, The Netherlands*

## **EDITORIAL ADVISOR**

*Lajos Balogh, AA Nanomedicine & Nanotechnology Consultants, Boston, Massachusetts, USA*

## **DE GRUYTER**

*published in cooperation with CLINAM – European Foundation for Clinical Nanomedicine*

The *European Journal of Nanomedicine (EJNM)* is covered by the following services: Celdes, CNKI Scholar (China National Knowledge Infrastructure), CNPIEC, EBSCO - TOC Premier, EBSCO Discovery Service, Elsevier - SCOPUS, Google Scholar, J-Gate, Naviga (Softweco), Paperbase, Pirabase, Polymer Library, Primo Central (ExLibris), SCImago (SJR), Summon (Serials Solutions/ProQuest), TDOne (TDNet), Ulrich's Periodicals Directory/ulrichsweb, WorldCat (OCLC)

*EJNM* places emphasis on the clinical application of nanoscience tools, methods and materials and the diverse implications of Nanomedicine. It aims to benefit patients by publishing clinically focused research.

The publisher, together with the authors and editors, has taken great pains to ensure that all information presented in this work (programs, applications, amounts, dosages, etc.) reflects the standard of knowledge at the time of publication. Despite careful manuscript preparation and proof correction, errors can nevertheless occur. Authors, editors and publisher disclaim all responsibility for any errors or omissions or liability for the results obtained from use of the information, or parts thereof, contained in this work.

The citation of registered names, trade names, trademarks, etc. in this work does not imply, even in the absence of a specific statement, that such names are exempt from laws and regulations protecting trademarks etc. and therefore free for general use.

ISSN 1662-5986 · e-ISSN 1662-596X

All information regarding notes for contributors, subscriptions, open access, back volumes and orders is available online at [www.degruyter.com/view/j/ejnm](http://www.degruyter.com/view/j/ejnm)

**RESPONSIBLE EDITORS** Prof. Dr. med. Patrick Hunziker, University Hospital Basel and European Foundation for Clinical Nanomedicine - CLINAM, Basel, CH, Email: [hunziker@clinam.org](mailto:hunziker@clinam.org)

Prof. Dr. Jan Mollenhauer, Head Molecular Oncology and Director Lundbeckfonden Center of Excellence NanoCAN, IMM - Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark, Email: [jmollenhauer@health.sdu.dk](mailto:jmollenhauer@health.sdu.dk)

Dr. med. h.c. Beat Löffler, CEO of the European Foundation for Clinical Nanomedicine - CLINAM, Basel, CH, Email: [loeffler@clinam.org](mailto:loeffler@clinam.org)

**SCIENTIFIC MANAGING EDITOR** Dr. Ing. Georgette B. Salieb-Beugelaar, University Hospital Basel, CH, Email: [beugelaar@swissnano.org](mailto:beugelaar@swissnano.org)

**JOURNAL MANAGER** Alexandra Hinz, De Gruyter, Genthiner Straße 13, 10785 Berlin, Germany, Tel.: +49 (0)30 26005-358, Fax: +49 (0)30 26005-184, Email: [Editorial.Nanomedicine@degruyter.com](mailto:Editorial.Nanomedicine@degruyter.com)

**RESPONSIBLE FOR ADVERTISEMENTS** Claudia Neumann, De Gruyter, Genthiner Straße 13, 10785 Berlin, Germany. Tel.: +49 (0)30 260 05-226, Fax: +49 (0)30 260 05-325, Email: [anzeigen@degruyter.com](mailto:anzeigen@degruyter.com)

© 2016 Walter de Gruyter GmbH, Berlin/Boston

**TYPESETTING** Compuscript Ltd., Shannon, Ireland

**PRINTING** Franz X. Stückle Druck und Verlag e.K., Ettenheim

Printed in Germany

**COVER ILLUSTRATION** The illustration presents the one-step method for radiolabeled multifunctional nanoparticles. Such quick and simple modification and radiolabeling facilitates clinical trials by selecting the proper nanoparticle. The review article "Translational Radionanomedicine: A Clinical Perspective" (pp. 71–84) presents recent advances and challenges for radionanomedicine including radiolabeling, modification, and in vivo behavior of nanoparticles. © Yun-Sang Lee



# Contents

## What's Up?

Georgette B. Salieb-Beugelaar

**What's up in nanomedicine? — 65**

## Special section Radionanomedicine

### Guest Editorial

Dong Soo Lee

**Radionanomedicine — 69**

### Review

Hongyoon Choi, Yun-Sang Lee, Do Won Hwang and Dong Soo Lee

**Translational radionanomedicine: a clinical perspective — 71**

### Perspective

Yun-Sang Lee and Jae Min Jeong

**A potentially versatile nano-platform — 85**

## Regular contributions

### Original Articles

Reza Mahjub, Robabeh Allahyar, Morteza Rafiee-Tehrani and Farid Abedin Dorkoosh

**Preparation and characterization of nanoparticles composed of methylated N-(4-N,N-dimethyl aminobenzyl) chitosan for oral delivery of cyclosporine A — 91**

Chukwuebuka Umeyor, Anthony Attama, Emmanuel Uronnachi, Chinazom Agbo, Joy Reginald-Opara and Franklin Kenekchukwu

**Formulation of gentamicin as surface modified self-nanoemulsifying formulations (SNEFs) improves its anti-pneumococcal activity — 101**